Cowen Starts Neuroderm Ltd (NDRM) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Roth Capital Starts Neuroderm Ltd (NDRM) at Buy
December 9, 2014 7:08 AM ESTRoth Capital initiated coverage on Neuroderm Ltd (NASDAQ: NDRM) with a Buy rating and a price target of $17.50.
For an analyst ratings summary and ratings history on Neuroderm Ltd click here. For more ratings news on Neuroderm Ltd click here.
Shares of Neuroderm Ltd closed at $8.04 yesterday.
... MoreJefferies Starts Neuroderm Ltd (NDRM) at Buy, $17 PT
December 9, 2014 6:49 AM ESTJefferies initiates coverage on Neuroderm Ltd (NASDAQ: NDRM) with a Buy rating and a price target of $17.00.
Analyst Thomas Wei said, "We view NDRM's Parkinsons disease (PD) assets, ND0612L and ND0612H, as two relatively de-risked drugs among mid-stage biotech... More
